Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exosomes as a platform for 'liquid biopsy' in pancreatic cancer
http://iopscience.iop.org/article/10.1088/2057-1739/aa5beb
Molecular and functional analysis of monoclonal antibodies in support of biologics development
21 July 2017
Acknowledgements
The authors thank Dr. Georgina Salazar at the University of Texas Health Science Center at Houston for her careful and critical reading of the manuscript, ......
https://link.springer.com/article/10.1007/s13238-017-0447-x
Yes! And they bought because of Avid and the worthless Bavi sector. Hmmmm
Oh no! They just pushed the wrong button.
Good news this morning Austria! Thx
PEREGRINE PHARMACEUTICALS INC -- DFAN14A
EDG
20/07/2017 6:43 PM
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20170720:EDG_0000921895-17-001954
nEOL7SmWvG
© Thomson Reuters 2017. All rights reserved.
Or it's Ronin playing pps
Revolution or king has lost his Crown. LOL
Phosphatidylserine Is the Signal for TAM Receptors and Their Ligands
http://www.cell.com/trends/biochemical-sciences/fulltext/S0968-0004(17)30110-X
High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181464
Search for PS year 2017
http://grantome.com/search?q=phosphatidylserine+
Inner Mitochondrial Membrane Disruption Links Apoptotic and Agonist-Initiated Phosphatidylserine Externalization in Platelets.
2017 Jun 29
https://www.ncbi.nlmv.nih.gov/pubmed/28663253
Microenvironmental Transport for Immunotherapy in Pancreatic Cancer
Fleming, Jason B.
Methodist Hospital Research Institute, Houston, TX, United States
......We have also developed biomimetic probes to study these phenomena in more detail and to develop novel immune-based therapies. Moreover, we have identified biophysical subtypes of PDAC, which exhibit distinct physical and immune properties, suggesting they will have differential responses to immunotherapies. We will couple these preliminary data with a well-characterized immune checkpoint: phosphatidylserine (PS). PS functions upstream of other immune checkpoints such as PD1 and CTLA4. Cells in the tumor microenvironment express PS, which is recognized and bound by PS receptors on immune cells to induce and maintain immune suppression. PS- targeting agents induce immune activation of innate and adaptive anti-tumor activity. We hypothesize that PS contributes to PDAC immune evasion in concert with the aberrant physics of PDAC, and that PS inhibition will normalize the biological and physical immunosuppression of PDAC. Our ultimate objective is to develop new ways to non-invasively measure and modulate the immunosuppression of PDAC to improve outcomes for this deadly disease.
http://grantome.com/grant/NIH/U54-CA210181-01-5161
https://moffitt.org/research-science/researchers/jason-fleming/
Project Start2016-08-29Project End2021-07-31Budget Start2016-08-29Budget End2017-07-31
LOL - few
HIV hijacks surface molecule to invade cell
https://www.nih.gov/news-events/news-releases/hiv-hijacks-surface-molecule-invade-cell
I think we had this already a view days ago.
I'm still a believer.
To get it very cheap. Imo
Thanks CP
That's exactly the reason why I' m not an the list too.
Yes! There is so much to find with PS and the problems with it but WHY is there no BP out there who opens its pocket for it.....or is there one behind the corner....
They wait until the smoke has gone and they / we have a clear view on what's going on. Nothing clear so far for me.
PEREGRINE PHARMACEUTICALS INC FILES AMENDED PROXY STATEMENT -- DEFA14A
EDG
14/07/2017 1:54 PM
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20170714:EDG_0001683168-17-001764
nEOL6pSSdb
© Thomson Reuters 2017. All rights reserved.
PEREGRINE PHARMACEUTICALS SAYS CURRENTLY EVALUATES DIRECTOR NOMINATIONS FROM SHAREHOLDERS PPHM.O
MIDTRD
14/07/2017 12:09 PM
06:06 AM EDT, 07/14/2017 (MT Newswires) -- Peregrine Pharmaceuticals (PPHM) said late Thursday that it will review the director nominations submitted by shareholders Ronin Trading and SW Investment Management.
The company said it is in talks with representatives of Ronin Trading and SW Investment Management to get 'constructive input' with the goal of 'enhancing value.'
Price: 5.41, Change: , Percent Change:
Copyright (c) 2017 MT Newswires, a Division of MidnightTrader, Inc. All rights reserved.
nNRA45171u
© Thomson Reuters 2017. All rights reserved.
HIV HIV HIV GILD GILD GILD HMMMMMM
NIH researchers discover key step in process of HIV hijack of surface molecule to invade cell
Maryland
Friday, July 14, 2017, 10:00 Hrs [IST]
Researchers at the National Institutes of Health (NIH) have discovered a key step in the process that HIV uses to inject its genetic material into cells. Working with cultures of cells and tissues, the researchers prevented the invasion process by chemically blocking this step, preventing HIV genetic material from entering cells. The findings could lead to the eventual development of new drugs to prevent HIV infection.
The study, appearing in Cell Host & Microbe, was led by Leonid V. Chernomordik, Ph.D., at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
To infect a cell, a protein on the surface of HIV binds to molecules on the cell’s surface. This binding process initiates a sequence of events that ends with HIV’s outer membrane fusing with the cell’s membrane. The virus’ genetic material then passes into the cell. The researchers discovered that the binding process activates a protein, called TMEM 16F, that transfers another molecule inside the cell membrane, phosphatidylserine, to the membrane’s outer surface. They believe molecules in the viral membrane bind with the exposed phosphatidylserine on the cell surface to enhance the virus’ fusion to the cell.
The researchers found that blocking the transfer of phosphatidylserine to the cell surface — or attaching another molecule to phosphatidylserine so it can’t bind with HIV — prevents the virus from infecting the cell. Theoretically, developing drugs that could block each of these steps could provide the basis for treatments to prevent HIV from infecting cells, but much more research is needed.
Leonid Chernomordik, Ph.D., study author and senior investigator in the NICHD Section on Membrane Biology, is available for comment.
http://www.pharmabiz.com/NewsDetails.aspx?aid=103122&sid=2
BRIEF-PEREGRINE PHARMACEUTICALS SAYS NOMINATING COMMITTEE WILL EVALUATE RONIN AND SWIM'S NOMINEES
RTRS
14/07/2017 2:14 AM
July 13 (Reuters) - Peregrine Pharmaceuticals Inc PPHM.O
Peregrine Pharmaceuticals issues statement regarding ronin trading and sw investment management’s letter to stockholders
Peregrine Pharmaceuticals inc says nominating committee will evaluate ronin/swim's nominees
Peregrine Pharmaceuticals-confirmed that ronin trading llc, sw investment management llc submitted 3 candidates for election to co's board at co's agm
Peregrine Pharmaceuticals Inc - 'we have engaged in various discussions with representatives of ronin trading and sw investment management'
Source text for Eikon: (Full Story) Further company coverage: PPHM.O
((Bangalore.newsroom@thomsonreuters.com;))
nFWN1K40PF
© Thomson Reuters 2017. All rights reserved.
Yes. But some one bought there.
BUZZ-PEREGRINE PHARMACEUTICALS INC: NEARS 1-1/2-YR HIGH
RTRS
13/07/2017 8:11 PM
** Drug developer's shares PPHM.O up as much as 14.8 pct at $5.50, highest since February 2016
** Activist investors Ronin Trading LLC and SW Investment Management LLC nominate Gregory Sargen, Brian Scanlan and Saiid Zarrabian for election to PPHM's board (Full Story)
** More than 1.2 mln shares traded, 5.3x 25-day moving avg; Stock's busiest day in nearly six months
** "We are extremely concerned by Peregrine's current strategy, the continuous dilution of stockholders and the company's exceptionally weak corporate governance" - Ronan and SW
** Ronin and SW collectively own about 8.8 pct of PPHM's outstanding shares, making them its second largest stockholder
** Peregrine, which issued a reverse stock split earlier this month, had 42.5 mln shares outstanding as of July 12 - TR data (Full Story)
** Up to Wednesday's close, PPHM stock more than doubled but since the company reported Q3 results on March 13, stock is down 10 pct
((RM: tamara.mathias.thomsonreuters.com@reuters.net))
nL4N1K44ZE
© Thomson Reuters 2017. All rights reserved.
OK let's say $360 - look at the chart year 2000
Vol now over 1 mio
The moon is at $400 after all those years and RSs for those owning PPHM for such a long time.
Could there be a link between Ronin and GILD. I'm still under the impression that GILD is having a shopping list.
PEREGRINE PHARMA SHARES EXTEND GAINS, NOW UP 9.3 PCT IN AFTERNOON TRADE AFTER RONIN TRADING AND SW INVESTMENT NOMINATE 3 CANDIDATES TO CO'S BOARD
RTRS
13/07/2017 7:11 PM
nFWN1K40MA
© Thomson Reuters 2017. All rights reserved.
The family
Avid is the diamond - and Bavi still a goldmine?
When I google for Bavi I get that link
http://www.utsouthwestern.edu/life-at/events/eventdetails.html?eventId=CAL-47726db9-33248210-0133-36e45adf-00001155demobedework%40mysite.edu-20170718T121500Z
Breast Conference - but there nothing to find with Bavi...
Why - help.......
Profits on friday? Or what else.
GILD or Novartis or someone else...mayby ....
Novartis chairman says open to deals worth at least $10 bln -paper - Reuters News
11-Jul-2017 16:32:32
** Novartis is open to paying at least $10 billion for a possible acquisition, Chairman Joerg Reinhardt told Swiss newspaper Finanz und Wirtschaft.
** "Yes I would also describe an acquisition in the low double-digit billion range as a bolt-on acquisition," Reinhardt was quoted as saying in the interview published on Tuesday.
** "If it makes sense, I would agree to such a deal. But the focus is on smaller transactions."
** Novartis has previously said it was keeping an eye out for bolt-on targets worth $2 billion-$5 billion.
That's what we all hope.......but we hope for quite a long time.....
467k x7= 3,3 mio pree RS